Related Experiment Video

Updated: May 9, 2026

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
14:04

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria

Published on: May 8, 2013

Emerging drugs on methicillin-resistant Staphylococcus aureus

Adamantia Liapikou1, Antoni Torres

  • 1Sotiria Hospital, 3rd Respiratory Department, Mesogion 152, 11527, Athens, Greece. mliapikou@yahoo.com

Expert Opinion on Emerging Drugs
|July 16, 2013
PubMed
Abstract

Insights

New antibiotics are emerging to combat Methicillin-resistant Staphylococcus aureus (MRSA) infections. Novel glycopeptides and oral agents show promise for future MRSA treatment strategies, offering new therapeutic options.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) is a significant cause of severe hospital and community-acquired infections.
  • Current treatment options for MRSA are limited, primarily relying on glycopeptides and linezolid.

Purpose of the Study:

  • To review current and emerging therapeutic agents for Methicillin-resistant Staphylococcus aureus (MRSA) infections.
  • To assess the potential of new antimicrobial agents in the evolving landscape of MRSA treatment.

Main Methods:

  • A comprehensive literature search was performed using PubMed and ClinicalTrials.gov.
  • Keywords included 'MRSA', 'MRSA therapy', 'new antibiotics', 'vancomycin', 'oritavancin', 'ceftaroline', 'linezolid', and 'tigecycline' for English-language articles published between 2000 and 2013.

Main Results:

  • Several new agents are under development for MRSA infections.
  • Newer glycopeptides like dalbavancin and oritavancin offer extended half-lives for less frequent dosing.
  • Oral agents such as iclaprim are being explored for outpatient MRSA therapy.

Conclusions:

  • The optimal role for new MRSA agents in therapeutic regimens is still being established.
  • Emerging treatments like long-acting glycopeptides and oral agents may expand outpatient treatment options.
  • Individualized treatment decisions considering the patient, infection site, and therapy setting are crucial for effective MRSA management.

More Related Videos

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat07:46

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat

Published on: June 4, 2012

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...